Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 22,100 shares, a decline of 6.0% from the March 15th total of 23,500 shares. Based on an average trading volume of 3,000 shares, the days-to-cover ratio is currently 7.4 days. Approximately 1.2% of the company’s shares are short sold.

Cyclerion Therapeutics Price Performance

Shares of CYCN stock traded down $0.14 on Tuesday, reaching $3.18. 527 shares of the stock were exchanged, compared to its average volume of 3,282. The stock has a market cap of $8.62 million, a PE ratio of -0.58 and a beta of 1.84. Cyclerion Therapeutics has a one year low of $1.75 and a one year high of $7.00. The stock has a 50 day moving average price of $3.12 and a 200 day moving average price of $3.07.

Institutional Investors Weigh In On Cyclerion Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in shares of Cyclerion Therapeutics by 0.9% during the first quarter. Geode Capital Management LLC now owns 592,237 shares of the company’s stock worth $257,000 after purchasing an additional 5,500 shares during the period. Renaissance Technologies LLC grew its stake in shares of Cyclerion Therapeutics by 50.7% during the second quarter. Renaissance Technologies LLC now owns 456,077 shares of the company’s stock worth $250,000 after purchasing an additional 153,519 shares during the period. Tyndall Capital Partners L P grew its stake in shares of Cyclerion Therapeutics by 11.3% during the fourth quarter. Tyndall Capital Partners L P now owns 164,429 shares of the company’s stock worth $551,000 after purchasing an additional 16,717 shares during the period. Prelude Capital Management LLC grew its stake in shares of Cyclerion Therapeutics by 25.9% during the second quarter. Prelude Capital Management LLC now owns 126,192 shares of the company’s stock worth $69,000 after purchasing an additional 25,937 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of Cyclerion Therapeutics during the second quarter worth $32,000. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is Zagociguat (CY6463), a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults.